effect of ph on rituximab production

The pH of the culture medium is an important parameter that affects the growth and productivity of cells in a bioreactor. The pH can affect the solubility, stability and activity of enzymes, as well as the uptake and metabolism of nutrients.

In the case of rituximab production, the pH can affect the stability and activity of the protein, as well as the productivity of the cells. Optimal pH for rituximab production in Chinese hamster ovary (CHO) cells usually ranges from 7.0 to 7.5. A pH that is too low or too high can cause the protein to denature or aggregate, reducing its activity and stability. Additionally, a pH that is too low or too high can also cause stress to the cells, reducing their productivity.

A research article "Development of a high-titer, high-density fed-batch process for the production of Rituximab in Chinese Hamster Ovary (CHO) cells" by Wang et al. (2015) aimed to improve the production of rituximab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the rituximab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein.

The results of the study showed that the optimal pH for rituximab production was 7.2 and the productivity of the cells was highest at that pH. Also, the study found that the quality of the protein was similar to that of the clinically used product, with a high degree of purity, stability, and bioactivity.

In conclusion, the pH of the culture medium is an important parameter that can affect the stability and activity of rituximab, as well as the productivity of the cells. It is important to maintain the pH within the optimal range to ensure the stability and activity of the protein and the productivity of the cells.

Comments

Post a Comment

Popular posts from this blog

article review on tocilizumab production

Tocilizumab (Actemra) is a humanized monoclonal antibody that targets the interleukin-6 (IL-6) receptor, which is involved in the inflammatory response. It is used to treat rheumatoid arthritis, systemic juvenile idiopathic arthritis and other inflammatory conditions. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. One research article "Development of an efficient and scalable fed-batch culture process for the production of tocilizumab in Chinese hamster ovary cells" by Li et al. (2019) aimed to optimize the production of tocilizumab using a fed-batch cultivation system in CHO cells. The study aimed to improve the yield and quality of the protein, and to develop a process that can be easily scaled up for industrial production. The results of the study showed that the yield of tocilizumab was significantly improved by optimizing the culture conditions, such as the temperature, pH, and dissolved oxygen, as well as by using a specific ...
Read more

article review on adalimumab production

Adalimumab is a recombinant human monoclonal antibody that is used to treat a variety of inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. A research article "Development of a high-titer, high-density fed-batch process for the production of adalimumab in CHO cells" by Chen et al. (2018) aimed to improve the production of adalimumab by developing a high-titer and high-density fed-batch process. The study used a CHO cell line that had been modified to express the adalimumab gene. The cells were grown in a culture medium containing glucose, amino acids, and a proprietary feed supplement, and the culture conditions were optimized to achieve high yields of the protein. The results of the study showed that a high yield of adalimumab (over 2g/L) was achieved using the fed-batch cultivation system. The study also found that the specific productivity of th...
Read more